Olwen Hahn

Alliance for Clinical Trials in Oncology — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

31h-index5.2kcitations140works7.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(37), Advanced Breast Cancer Therapies(34), Cancer Treatment and Pharmacology(28), Renal cell carcinoma treatment(19), Cancer Genomics and Diagnostics(16)

Publications139 total

Spatial transcriptomic profiling of metastatic renal cell carcinoma identifies Chemokine-Driven macrophage and CD8+ T cell interactions predictive of immunotherapy response
European Urology Open Science·2025Open Access
DISP-33. Approaches to Utilization of Proton Radiotherapy in Primary and Secondary Brain Tumors as a Scarce Resource: A Qualitative Analysis of Physician Perspectives
Neuro-Oncology·2025Open Access
2669eP Spatial transcriptomics reveal macrophage-enriched chemokine niches in metastases defining immunotherapy response in renal cell carcinoma
Annals of Oncology·2025
Impact of a Weight Loss Intervention on 1-Year Weight Change in Women With Stage II/III Breast Cancer
JAMA Oncology·2025· 1 citedOpen Access
Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/persistent epithelial ovarian cancer
Breast Cancer Research and Treatment·2025Open Access
Abstract RF1-01: Effect of a weight loss intervention (WLI) on metabolic and inflammatory biomarkers in women with obesity and breast cancer: Results from the Breast Cancer Weight Loss (BWEL) Trial (Alliance)
Clinical Cancer Research·2025
Abstract P3-06-15: Trajectories of Daily Step Counts in Breast Cancer Survivors in the Breast Cancer Weight Loss (BWEL) Trial
Clinical Cancer Research·2025
Association of lifestyle factors and pathological characteristics in patients with early breast cancer and overweight/obesity: Results from the Breast Cancer Weight Loss (BWEL) trial.
Journal of Clinical Oncology·2025
A0669 – Metastatic renal cell carcinoma: De novo vs. secondary metastatic disease and its impact on cancer control in the IO-combination era —real world experiences from a multi-institutional cohort
European Urology·2025
A0768 – Adjuvant therapy with pembrolizumab in renal cell carcinoma: real-world experiences from a retrospective, multi-institutional cohort
European Urology·2025
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer
Breast Cancer Research and Treatment·2025· 2 citedOpen Access
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer
Journal of Oncology Pharmacy Practice·2024· 1 cited
A Randomized Phase II Trial of Nab-paclitaxel with or without Mifepristone for Advanced Triple-Negative Breast Cancer
2024· 1 citedOpen Access
Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer
Journal of Oncology Pharmacy Practice·2024
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer
Carolina Digital Repository (University of North Carolina at Chapel Hill)·2024Open Access
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination
UNC Libraries·2024· 1 citedOpen Access
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
New England Journal of Medicine·2024· 126 citedOpen Access
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer.
Journal of Clinical Oncology·2024
Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer (ABCSG-42/AFT-05/BIG-14-13).
Journal of Clinical Oncology·2024
Abstract PO3-02-05: Racial and Ethnic Differences in Clinical Outcomes among North American Patients with Hormone Receptor-Positive, HER2-negative, Early Breast Cancer in the PALLAS Trial (AFT-05)
Cancer Research·2024
page 1 of 7Next →

Frequent Co-authors

Michael J. Morris(15), Eric P. Winer(14), Lisa A. Carey(12), Susan Halabi(12), Eric J. Small(12), Clifford A. Hudis(10), Ann H. Partridge(8), Charles M. Perou(6), Joel Picus(6), Walter M. Stadler(6), Karla V. Ballman(6), Colleen Watt(6), Donald A. Berry(5), Sara M. Tolaney(5), Toni K. Choueiri(5), M. Dror Michaelson(5), Meghara Walsh(5), Shaker R. Dakhil(5), Daniel J. George(5), William T. Barry(5)